pharmaphorum

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Fierce Pharma

Amgen, AZ's Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
FiercePharma

Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary ...
Healio

FDA approves Dupixent for bullous pemphigoid

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.
Wall Street Journal

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in the ...

Sanofi and Regeneron's Dupixent wins EU approval to treat children

Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product has won approval from the European Commission to treat children aged 6-11 suffering from severe atopic dermatitis, ...